Anti-gonadotrophin releasing hormone vaccine - ML Laboratories/Protherics

Drug Profile

Anti-gonadotrophin releasing hormone vaccine - ML Laboratories/Protherics

Alternative Names: GnRH immunotherapeutic; GnRH vaccine - ML Laboratories/Protherics; GnRHi; O14L; PM-OV-92; Prolog

Latest Information Update: 22 Jun 2004

Price : $50

At a glance

  • Originator Protherics
  • Class Antiandrogens; Antiprogestogens; Vaccines
  • Mechanism of Action Estrogen receptor antagonists; Gonadotropin releasing hormone inhibitors; Immunostimulants; Progesterone receptor antagonists; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 22 Jun 2004 Discontinued - Phase-II for Prostate cancer in United Kingdom (unspecified route)
  • 09 Jul 2001 Preliminary results of a phase II trial revealed that GnRHi did not elicit large reductions in testosterone levels and ML Laboratories may be about to discontinue the vaccine's development
  • 01 Sep 2000 A phase II study of the new formulation of Prolog® in patients with late-stage prostate cancer is underway in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top